Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in epididymal principal cells | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 52 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10606
Sealed predictions
- SLC30A3 in dopamine neurons, braak-0.33 (p 0.389) → +0.21 (p 0.588)receipt 10613
Swarm cases
receipt 10613: SLC30A3 in dopamine neurons, braak
- power
- full sample -0.10 (p 0.690, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.754, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.239, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.02, sign flips 3; without severely affected donors -0.10 (p 0.690, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC30A3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts